• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Canada·Healthcare·BLCO
Held by 5 Gurus
Share

Bausch + Lomb Corporation Stocks

$ 18.04Last Updated 04.09.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

$ 6.44B

$ 18.04
Key Takeaways

Risk factor

Resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Howard Marks

Portfolio Weight (%)

0.8%

Change

-0.13%

Fund

Oaktree Capital Management

Carl Icahn

Portfolio Weight (%)

0.7%

Change

+0.05%

Fund

Icahn Capital Management

Daniel Loeb

Portfolio Weight (%)

0.0%

Change

+0.03%

Fund

Third Point

Manager
Fund
Portfolio Weight (%)
Change
Howard MarksOaktree Capital Management0.8%-0.13%
Carl IcahnIcahn Capital Management0.7%+0.05%
Daniel LoebThird Point0.0%+0.03%
Show more

Latest news

03.03.2026 12:37

Aviation, pharma and bitcoin miner: how billionaire Howard Marks' portfolio has changed

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA, r

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of BLCO is 18.8 and suggests 3.94% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

07.09.2026 15:46

Iran announced that an agreement with Oman on traffic in the Strait of Hormuz would soon be reached

07.09.2026 14:56

OpenAI's new AI model pushed emerging market stocks to a two-month high

07.09.2026 14:10

Tyra shares are having their best day in 10 months. Investors are awaiting new data on its drug

07.09.2026 13:11

U.S. inflation, Apple's latest products, Oracle's earnings report: What Investors Need to Know This Week

07.09.2026 12:22

Brent surged to $98. U.S. officials said the nuclear deal with Iran might not go through

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026